: 10/009,916

Filed

August 13, 2002

AMENDMENTS TO THE CLAIMS

- 1. **(Previously presented)** An isolated or recombinant immunogenic polypeptide comprising a *Lawsonia spp*. SodC Polypeptide, a variant, or a truncated variant thereof, wherein said variant or truncated variant mimics or cross-reacts with a B-cell or T-cell epitope of *Lawsonia spp*. SodC Polypeptide.
- 2. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 1 wherein said polypeptide elicits the production of antibodies against *Lawsonia* spp. when administered to an avian or porcine animal.
- 3. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 1 which confers a protective immune response against *Lawsonia spp.* when administered to an avian or porcine animal.
- 4. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 1 wherein the *Lawsonia spp. is L. intracellularis*.

Claim 5 (Cancelled)

- 6. (Previously presented) An isolated or recombinant immunogenic polypeptide comprising:
- (i) a peptide, oligopeptide or polypeptide comprising an amino acid sequence which has at least about 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1; or
- (ii) a peptide, oligopeptide or polypeptide which comprises an amino acid sequence having at least about 50% sequence identity to amino acid residues 1 to 42 of SEQ ID NO:1; or
- (iii) a homologue or derivative of (i) or (ii) which mimics a B-cell or T-cell epitope of a Lawsonia spp. SodC polypeptide.
- 7. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 6 wherein said polypeptide elicits the production of antibodies against *Lawsonia* spp. in a porcine or avian animal.
- 8. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 6 wherein said polypeptide confers a protective immune response against *Lawsonia spp.* in a porcine or avian animal.

Claim 9 (Cancelled)

10/009,916

Filed

August 13, 2002

10. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 8, wherein said protective immune response is induced in a porcine animal.

11. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 6 wherein the *Lawsonia spp.* is *L. intracellularis*.

Claim 12 (Cancelled)

- 13. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 6 comprising the amino acid sequence set forth in SEQ ID NO: 1 or the amino acid sequence encoded by the SodC-encoding nucleotide sequence of pALK14 (ATCC 207155).
- 14. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 13 consisting essentially of the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence encoded by the SodC-encoding nucleotide sequence of pALK14 (ATCC 207155).

Claim 15-16 (Cancelled)

- 17. **(Previously presented)** The isolated or recombinant immunogenic polypeptide of claim 6 comprising amino acid residues about 1 to about 42 of SEQ ID NO:1 wherein said polypeptide elicits the production of antibodies against *Lawsonia intracellularis* when administered to an avian or porcine animal.
- 18. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 17 that consists essentially of about amino acid 1 to about amino acid 42 of SEQ ID NO: 1.
- 19. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 17 which induces a protective immune response against *Lawsonia* intracellularis in a porcine or avian animal.
- 20. (Previously presented) The isolated or recombinant immunogenic polypeptide of claim 19 which induces a protective immune response against *Lawsonia* intracellularis in a porcine animal.
- 21. (Previously presented) A vaccine composition for the prophylaxis or treatment of infection of an animal by *Lawsonia* spp., said vaccine composition comprising an effective amount of an immunogenic component comprising an isolated or recombinant polypeptide having at least about 70% sequence identity to the amino acid sequence set forth in

: 10/009,916

Filed

August 13, 2002

SEQ ID NO: 1 or at least about 50% sequence identity to amino acid residues 1 to 42 of SEQ ID NO:1 or an immunogenic homologue, or derivative thereof which is immunologically cross-reactive with *Lawsonia intracellularis*; and one or more carriers, diluents or adjuvants suitable for veterinary or pharmaceutical use.

- 22. **(Previously presented)** The vaccine composition according to claim 21 wherein the *Lawsonia spp.* is *L. intracellularis*.
- 23. (Currently Amended) The vaccine composition according to claim 20 21 wherein the isolated or recombinant polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or the amino acid sequence encoded by the SodC-encoding nucleotide sequence of pALK14 (ATCC 207155).

Claim 24 (Cancelled)

- 25. (Previously presented) The vaccine composition according to claim 22 wherein the immunogenic component comprises an isolated or recombinant polypeptide that comprises about amino acid residue 1 to about amino acid residue 42 of SEQ ID NO: 1.
- 26. (Previously presented) The vaccine composition of claim 25, wherein the immunogenic component consists essentially of about amino acid 1 to about amino acid 42 of SEQ ID NO: 1.
- 27. (Currently Amended, Withdrawn) A combination vaccine composition for the prophylaxis or treatment of the infection of an animal by *Lawsonia* spp., said vaccine composition comprising:
- (i) a first immunogenic component comprising an isolated or recombinant polypeptide having at least about 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1 or at least about 50% sequence identity to amino acid residues 1 to 42 of SEQ ID NO:1or an immunogenic homologue or derivative thereof which is immunologically eross-reactive with Lawsonia intracellularis—immunogenic polypeptide according to Claim 6;
- (ii) a second immunogenic component comprising an antigenic *L. intracellularis* peptide, polypeptide or protein; and
- (iii) one or more carriers, diluents or adjuvants suitable for veterinary or pharmaceutical use.

Claims 28 - 35 (Cancelled)

10/009,916

Filed

August 13, 2002

36. (Withdrawn) A method of identifying a previous or current infection with *Lawsonia intracellularis* or a microorganism that is immunologically cross-reactive thereto, said method comprising:

contacting blood or serum from said animal with the immunogenic polypeptide of claim 1 for a time and under conditions sufficient for an antigen: antibody complex to form; and detecting said complex formation.

Claims 37 - 47 (Cancelled)

- 48. (Withdrawn) The combination vaccine according to claim 27 wherein the second immunogenic component is selected from the group consisting of OmpH, FlgE, hemolysin and autolysin.
- 49. (Previously presented) The vaccine composition of claim 23, wherein the isolated or recombinant polypeptide consists essentially of the amino acid sequence of SEQ ID NO: 1.
- 50. (NEW) An isolated or recombinant immunogenic polypeptide comprising a *Lawsonia spp.* SodC Polypeptide.
- 51. **(NEW)** The isolated or recombinant immunogenic polypeptide of claim 1 wherein said polypeptide elicits the production of antibodies against *Lawsonia* spp. when administered to an avian or porcine animal.
- 52. **(NEW)** The isolated or recombinant immunogenic polypeptide of claim 1 which confers a protective immune response against *Lawsonia spp*. when administered to an avian or porcine animal.
- 53. **(NEW)** The isolated or recombinant immunogenic polypeptide of claim 1 wherein the *Lawsonia spp. is L. intracellularis*.
- 54. **(NEW)** An isolated or recombinant immunogenic polypeptide comprising a peptide, oligopeptide or polypeptide comprising SEQ ID NO: 1.
- 55. **(NEW)** The isolated or recombinant immunogenic polypeptide of claim 8, wherein said protective immune response is induced in a porcine animal.
- 56. (NEW) A vaccine composition for the prophylaxis or treatment of infection of an animal by *Lawsonia* spp., said vaccine composition comprising an effective amount of an immunogenic component comprising an isolated or recombinant polypeptide comprising amino acids 1 to 42 of SEQ ID NO:1 which is immunologically cross-reactive with

Appl. No. : 10/009,916

Filed : August 13, 2002

Lawsonia intracellularis; and one or more carriers, diluents or adjuvants suitable for veterinary or pharmaceutical use.

57. **(NEW)** The vaccine composition according to claim 21 wherein the *Lawsonia spp.* is *L. intracellularis*.